China Leads The Coronavirus Vaccine Race
BioSpectrum Asia|October 2020
Of the nine leading candidate that are under Phase III trial for the novel coronavirus in the world, five are from China- a most from any country. China has emerged as a leader in the novel coronavirus vaccines, a development that will enhance it as a global power but also raises concerns over safety and efficacy of the vaccine. Let’s look into the pros and cons of its leadership in the COVID-19 vaccine.
Ayesha Siddiqui
China Leads The Coronavirus Vaccine Race

Almost a year later, the country, which was the epicenter of the novel coronavirus has also emerged as a leader in the COVID-19 vaccines, a development that will enhance its standing as a global super power. Of the 40 new vaccines in clinical trials around the world, 11 are in China, the most of any country (as on September 25, 2020). Of the nine that are in Phase III, China has five. Chinese vaccines are expected to launch as early as December 2020.

Unlike western countries, which are hedging bets on the experimental vaccines, China is betting big on the tried and tested capabilities of inactivated vaccines. Five companies in the world that are pursuing inactivated coronavirus vaccines, four are Chinese, including Sinovac and two vaccines from state owned China National Pharmaceutical Group Co., Ltd. (Sinopharm). Earlier there were concerns about whether inactivated vaccines for the new coronavirus will work, but after AstraZeneca’s scandal in early September 2020 where the firm had to halt the trials because of adverse reaction, experts, now believe this old school method of vaccine might actually prove successful this time around as well.

While most of the Chinese companies are working independently, two of them - Fosun Pharma and Clover Biopharmaceuticals have partnered with international firms to develop the vaccine.

Fosun Pharma is partnering with US’ Pfizer and Germany’s BioNTech. In August 2020, BioNTech and Fosun Pharma announced the start of clinical trial of mRNA-based COVID-19 vaccine candidate in China.

This story is from the October 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the October 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView All
Korea designs sweat resistant wearable robot sensor
BioSpectrum Asia

Korea designs sweat resistant wearable robot sensor

New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.

time-read
1 min  |
March 2024
Why Singapore is Deep Tech Innovation Frontrunner
BioSpectrum Asia

Why Singapore is Deep Tech Innovation Frontrunner

Move over Artificial Intelligence Al) and Machine Learning ML), there's a new technology on the block Deep Tech. This latest technology holds immense potential for the life sciences industry, and Singapore is leaving no stone unturned in becoming a deep tech hub. From strategic investments to collaborative initiatives and a supportive regulatory environment, read on to find out about the country's initiatives in becoming a deep tech superpower.

time-read
4 mins  |
March 2024
Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?
BioSpectrum Asia

Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?

The World Health Organization (WHO) has taken a significant stride in the battle against Tuberculosis (TB) by introducing shorter drug regimens, aiming to curb a disease that claims countless lives globally. This innovative approach addresses the urgent need for more efficient treatments, especially in regions where TB's toll is highest. With traditional therapies often posing risks to liver health, these shortened regimens offer hope, minimising such concerns while enhancing treatment adherence.

time-read
5 mins  |
March 2024
How pharma is finally researching issues that primarily affect women
BioSpectrum Asia

How pharma is finally researching issues that primarily affect women

Pharma is now concentrating on problems that impact women. Female participation will now directly contribute to cures for diseases that affect them, since more studies specifically targeted at women are planned.

time-read
8 mins  |
March 2024
Championing PAY PARITY
BioSpectrum Asia

Championing PAY PARITY

Despite women's significant strides and contributions in the healthcare field, they are paid less than men. Unfortunately, as is the case in most spheres, persistent pay disparities plague the life sciences sector. How big is the gender pay gap in the pharma industry? Are companies and the industry doing enough to address this issue? Let's find out.

time-read
6 mins  |
March 2024
ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES
BioSpectrum Asia

ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES

Globally, women constitute 46 per cent of the workforce in the public sector, whereas in the private sector, they represent 33 per cent. The public sector maintains a higher representation of women as employees compared to the private sector as per data from the World Bank.

time-read
10+ mins  |
March 2024
US FDA approves first medication to treat severe frostbite
BioSpectrum Asia

US FDA approves first medication to treat severe frostbite

The US Food and Drug Administration (FDA) has approved Eicos Sciences Inc’s Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

time-read
1 min  |
March 2024
Japanese startup RevolKa to create highly functional proteins by using AI-driven platform
BioSpectrum Asia

Japanese startup RevolKa to create highly functional proteins by using AI-driven platform

RevolKa, a venture-backed biotech startup providing a gamechanging protein engineering technology platform, based in Japan, has signed a contract research agreement with Sekisui Chemical.

time-read
1 min  |
March 2024
Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development
BioSpectrum Asia

Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development

Taiwan-based startup Anbogen Therapeutics, a clinical-stage biotechnology company specialising in groundbreaking cancer drug development, has announced the successful completion of its Series A funding round.

time-read
1 min  |
March 2024
Samsung Biologics & LegoChem Biosciences team up for ADC development
BioSpectrum Asia

Samsung Biologics & LegoChem Biosciences team up for ADC development

South Korea-based Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has signed a partnership agreement with LegoChem Biosciences, a Korean biotech company pioneering the research and development of antibody-drug conjugate (ADC) programmes.

time-read
1 min  |
March 2024